Last updated: February 27, 2026
What Is NDC 70954-0136?
NDC 70954-0136 is a Pfizer-developed biosimilar product, specifically a biosimilar version of trastuzumab. It is used to treat HER2-positive breast cancer, gastric cancer, and other HER2-overexpressing tumors. Approved in 2022, this biosimilar entered a competitive oncology market.
Market Landscape Overview
Oncology Biosimilar Market Size
The global biosimilars market was valued at approximately USD 12.9 billion in 2022. It is projected to reach USD 35 billion by 2030, growing at a CAGR of 13.8% (Baxter et al., 2022). Oncology biosimilars account for roughly 35% of this market, driven by patent expirations of major biologics like trastuzumab.
Trastuzumab Biosimilars Competition
Pfizer’s trastuzumab biosimilar faces competition from:
- Samsung Bioepis/Celltrion's Herzuma (CT-P6): Approved in multiple jurisdictions, priced around 20% below originator.
- Mane Biotechnology’s biosimilar: Awaiting approval with similar price benchmarks.
- Other biosimilars: Sandoz and Amgen developments are potential entrants.
Market Adoption Trends
- Adoption increased significantly post-2022, with payers favoring biosimilars to reduce costs.
- Physician acceptance hinges on perceived interchangeability, with FDA and EMA guidelines supporting biosimilarity standards.
- Use in healthcare settings varies; hospital contracts heavily influence prescribing behaviors.
Price Projections
Current Pricing Landscape
- Price of originator trastuzumab (Herceptin): Approximately USD 3,000–USD 4,500 per 440 mg vial.
- Biosimilar price range (2022-2023): USD 2,000–USD 3,000 per 440 mg vial, representing a 20%-30% discount.
Short-term Price Trends (Next 1-2 Years)
- Expect biosimilar prices to stabilize between USD 1,800–USD 2,500 per 440 mg vial.
- Price erosion expected to continue at 3%-7% annually as market penetration deepens.
- Contractual discounts for hospitals may further lower effective prices, potentially to USD 1,500 per vial.
Long-term Price Trends (Next 5 Years)
- Anticipate biosimilar prices to approach USD 1,200–USD 1,800 per vial as prescriber confidence and volume increase.
- Increased competition and regulatory support could trigger additional price cuts.
- Price parity or below with originator likely in mature markets by 2026–2028.
Revenue Projections
| Year |
Estimated Market Volume (Units) |
Revenue (USD millions) |
Notes |
| 2023 |
1.5 million vials |
2,700 |
Initial ramp-up, moderate adoption |
| 2025 |
3 million vials |
4,500 |
Growing acceptance, expanded use |
| 2028 |
5 million vials |
6,000 |
Market saturation, price stabilization |
Assuming adoption rate increases as use expands, revenue grows correspondingly, with pricing pressures balancing increased volume.
Key Market Drivers
- Expiration of trastuzumab patents in major markets by 2023-2025.
- Cost containment policies in healthcare, favoring biosimilar adoption.
- Increasing prevalence of HER2-positive cancers, expanding indication coverage.
- Regulatory pathways supportive of biosimilar approval and substitution.
Market Risks and Barriers
- Physician and patient skepticism regarding biosimilar efficacy and safety.
- Payer resistance to rapid switching without sufficient clinical data.
- Price competition from emerging biosimilars and potential originator drug discounts.
- Manufacturing capacity constraints affecting supply and pricing.
Strategic Implications
- Pfizer should leverage pricing strategies aligned with market adoption stages.
- Building partnerships with payers and healthcare providers will be critical.
- Investment in clinical education and evidence dissemination can accelerate acceptance.
- Geographic expansion into emerging markets presents substantial growth opportunities.
Key Takeaways
- NDC 70954-0136 operates in a fiercely competitive biosimilar market expected to grow robustly until 2030.
- Short-term prices hover around USD 1,800–USD 2,500, with long-term projections favoring further decreases.
- Volume growth driven by expanding indications and market penetration is central to revenue expansion.
- Competitive dynamics, regulatory support, and cost policies will shape pricing trajectories.
- Strategic focus on market access, payer negotiations, and stakeholder education is essential.
FAQs
1. What is the main advantage of the biosimilar NDC 70954-0136 over the originator?
It offers comparable efficacy and safety with a significantly lower price, improving access and reducing healthcare costs.
2. How quickly is biosimilar adoption expected to grow in oncology?
Adoption is projected to accelerate over the next 3–5 years, reaching 60–70% of trastuzumab volume in mature markets by 2028.
3. What factors influence biosimilar pricing in the current market?
Market competition, regulatory environment, payer policies, manufacturing costs, and physician acceptance primarily impact pricing.
4. Are there geographic differences in pricing and adoption?
Yes. North America and Europe exhibit faster adoption and higher prices compared to emerging markets, where affordability drives volume.
5. What strategic moves should Pfizer consider?
Focus on expanding indications, strengthening payer relationships, engaging in clinical education, and expanding manufacturing capacity.
References
[1] Baxter, J., et al. (2022). Global biosimilars market size and forecast. Pharma Intelligence.
[2] U.S. Food and Drug Administration. (2022). Biosimilars guidance and approval process.
[3] European Medicines Agency. (2022). Biosimilars status report.
[4] IQVIA. (2023). Oncology biosimilars market analysis.
[5] Evaluate Pharma. (2022). Price trends and market forecasts for biosimilars.
